| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ueda Y, Sugawa H, Akamizu T, Okuda J, Ueda M, Kosugi S, Ohta C, Kihou Y, Mori T. Thyroidstimulating antibodies in sera from patients with Graves' disease are heterogeneous in epitope recognition. Eur J Endocrinol 1995;132:62–8. ISSN 0804–4643
Two synthetic peptides, P354-14 (amino acid nos. 354 to 367) and P338-16 (nos. 338 to 353), corresponding to the partial amino acid sequences of the hTSH receptor structure were studied for their ability to bind specifically serum IgGs from patients with Graves' disease and to inhibit thyroid stimulating TSH receptor antibody (TSH-R SAb) activity. IgG binding was measured by an ELISA using sera from 102 Graves', 20 Hashimoto patients, and 9 normal subjects. Both peptides showed significantly increased IgG binding of Graves' sera compared with those of Hashimoto and normal sera. There was a significant correlation (r = 0.529) between the amount of IgG bound by the two peptides, but neither of these values correlated well with their TSH-R SAb activity nor thyrotropin-binding inhibitor TSH receptor antibody (TSH-R IAb) activity. TSH-R SAb inhibiting effects of these peptides were then analysed by measuring TSH-R SAb activity after incubation with the peptides. Among eight Graves' IgGs tested the TSH-R SAb activity of three was inhibited by both peptides, two were inhibited only by P354-14 and three were not affected by either. These TSH-R SAb inhibiting effects were dose-dependent and reproducible. To confirm these findings, a peptide-sepharose gel affinity absorption study was performed. Eleven Graves' IgGs were applied to both peptide gels and the TSH-R SAb activity of the unabsorbed fraction was measured. The TSH-R SAb activity of five IgGs was strongly absorbed only by P354-14 and five others were absorbed by both peptides to an almost similar extent. One IgG was not affected by either of the peptides. None of the IgG activities tested was absorbed only or predominantly by P338-16. Most of Graves' IgGs could bind to region no. 338 to no. 367 of the hTSH receptor. There was apparent heterogeneity among Graves' TSH-R SAb IgGs as shown by their absorption by the peptides, and the existence of at least three heterogeneous species in epitopic recognition among Graves' TSH-R SAb was demonstrated.
Toru Mori, Department of Laboratory Medicine, Kyoto University School of Medicine, 54-Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-01, Japan
This article has been cited by other articles:
|
|
 |
|
  T. Ando, R. Latif, S. Daniel, K. Eguchi, and T. F. Davies Dissecting Linear and Conformational Epitopes on the Native Thyrotropin Receptor Endocrinology, November 1, 2004; 145(11): 5185 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Na, M. H. Lee, B. Y. Cho, and C.-B. Chae A Method for Identification of the Peptides That Bind to a Clone of Thyroid-Stimulating Antibodies in the Serum of Graves' Disease Patients J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Kim, Y. J. Park, D. J. Park, H.-K. Chung, W. B. Kim, L. D. Kohn, and B. Y. Cho Epitope Heterogeneity of Thyroid-Stimulating Antibodies Predicts Long-Term Outcome in Graves' Patients Treated with Antithyroid Drugs J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. C. Kung, K. S. Lau, and L. D. Kohn Epitope Mapping of TSH Receptor-Blocking Antibodies in Graves' Disease That Appear during Pregnancy J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3647 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Cerbo, R. Di Paola, C. Menzaghi, V. De Filippis, K. Tahara, D. Corda, and L. D. Kohn Graves' Immunoglobulins Activate Phospholipase A2 by Recognizing Specific Epitopes on Thyrotropin Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3283 - 3292. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Lee, J. Y. Park, B. Y. Cho, and C.-B. Chae Expression of the Functional Extracellular Domain of Human Thyrotropin Receptor Using a Vaccinia Virus System: Its Purification and Analysis of Autoantibody Binding J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1391 - 1397. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kikuoka, N. Shimojo, K.-I. Yamaguchi, Y. Watanabe, A. Hoshioka, A. Hirai, Y. Saito, K. Tahara, L. D. Kohn, N. Maruyama, et al. The Formation of Thyrotropin Receptor (TSHR) Antibodies in a Graves' Animal Model Requires the N-Terminal Segment of the TSHR Extracellular Domain Endocrinology, April 1, 1998; 139(4): 1891 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Patibandla, J. S. Dallas, G. S. Seetharamaiah, K. Tahara, L. D. Kohn, and B. S. Prabhakar Flow Cytometric Analyses of Antibody Binding to Chinese Hamster Ovary Cells Expressing Human Thyrotropin Receptor J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1885 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Kim, H. K. Chung, H. K. Lee, L. D. Kohn, K. Tahara, and B. Y. Cho Changes in Epitopes for Thyroid-Stimulating Antibodies in Graves' Disease Sera During Treatment of Hyperthyroidism: Therapeutic Implications J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1953 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Park, I. J. Kim, M. H. Lee, J. K. Seo, P. G. Suh, B. Y. Cho, S. H. Ryu, and C.-B. Chae Identification of the Peptides That Inhibit the Stimulation of Thyrotropin Receptor by Graves' Immunoglobulin G from Peptide Libraries Endocrinology, February 1, 1997; 138(2): 617 - 626. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
